Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Drug Correction of Vascular Remodeling in Patients with Hypertension: Results of 52-Week Prospective Study ARTERIA-AG

https://doi.org/10.20996/1819-6446-2020-04-08

Full Text:

Abstract

Aim. To study the long-term dynamics of vascular remodeling in patients with hypertension and high and very high cardiovascular risk when statin is added to antihypertensive therapy with a fixed combination of calcium antagonist and angiotensin converting enzyme (ACE) inhibitor.

Material and methods. Hypertensive patients (n=75) with high and very high cardiovascular risk (age 51.5 [44;58] years) were included in the study. Patients were randomized into two groups. The first group (n=36) received a fixed combination of amlodipine and lisinopril in starting dose of 5/10 mg/day. The second group (n=39) received the same antihypertensive therapy and additionally rosuvastatin (20 mg/day). The follow-up period was 52 weeks. The effect of therapy on the following parameters was evaluated: level of office and average daily blood pressure (BP), central BP in the aorta, augmentation index (AIx), pulse wave velocity (PWV), endothelium-dependent brachial artery vasodilation, carotid intima-media complex thickness, carotid arteries plaque height, and blood lipid profile indicators.

Results. A significant decrease in office and average daily BP was found in both groups: from 171.5 (152;194)/104.5 (97;112) to 140.0 (129;154)/87.0 (83;95) mm Hg and from 142.1 (135;153)/86.7 (83;97) to 124.6 (119;133)/76.5 (73;80) mm Hg, respectively, in the 1st group; from 169.5 (160;190)/103.5 (95;109) to 135.0 (125;141)/83.0 (77;88) mm Hg and from 139.9 (136;152)/86.2 (80;92) to 125.1 (118;134)/74.0 (70;81) mm Hg, respectively, in the 2nd group (p<0.001 for all changes). The frequency of reaching the target office BP level was higher in the 2nd group (p=0.031). Significant decrease in total cholesterol by 33.1% and low-density lipoprotein cholesterol by 50.0% was observed in the group 2. Central BP in the aorta decreased in both groups; the degree of central BP reduction did not differ significantly. AIx decreased from 36.5 (24;41)% to 25.0 (15;36)% (p=0.04) in the 1st group and from 36.0 (30;41)% to 24.0 (20;32)% in the 2nd group (p<0.0001) with a more pronounced decrease in AIx after 24 weeks of therapy (-4.8% and -9.4%, respectively, p=0.036). This trend continued at the end of the observation (-6.4% and -10.8%, respectively, p=0.08). Carotid-femoral and carotid-radial PWV decreased only in the 2nd group from 9.5 (8.2;10.7) to 8.3 (7.6;8.9) m/s (p=0.003) and from 9,6 (8.5;10.6) to 8.4 (7.9;9.3) m/s (p=0.01), respectively. A significant decrease in the thickness of the intima-media from 1.08 (1.0;1.2) to 1.02 (0.9;1.1) cm (p<0.0001) and the height of the plaque from 2.2 (2,2;1.7) to 2.1 (2.1;1.7) mm (p=0.001) was found in the 2nd group.

Conclusion. Addition of rosuvastatin to the fixed combination of amlodipine and lisinopril in treatment of hypertensive patients with high and very high cardiovascular risk was accompanied by a more frequent (compared with amlodipine and lisinopril only) achievement of the target office BP level and more pronounced reduction in the following indicators: augmentation index, carotid-femoral and carotid-radial PWV, intima-media thickness, plaque height, total cholesterol and low density lipoprotein cholesterol blood levels.

About the Authors

O. V. Fedorishina
Irkutsk State Medical Academy of Postgraduate Education – branch of Russian Medical Academy of Continuing Professional Education
Russian Federation

Olga V. Fedorishina – MD, PhD, Associate Professor, Chair of Cardiology and Functional Diagnostics

Yubileinii m-on 100, Irkutsk, 664049



K. V. Protasov
Irkutsk State Medical Academy of Postgraduate Education – branch of Russian Medical Academy of Continuing Professional Education
Russian Federation

Konstantin V. Protasov – MD, PhD, Professor, Head of Chair of Cardiology and Functional Diagnostics

Yubileinii m-on 100, Irkutsk, 664049



A. M. Torunova
Irkutsk State Medical Academy of Postgraduate Education – branch of Russian Medical Academy of Continuing Professional Education
Russian Federation

Anna M. Torunova – MD, Assistant, Chair of Therapy

Yubileinii m-on 100, Irkutsk, 664049



References

1. Muromtseva G.A., Kontsevaya A.V., Konstantinov V.V., et al. The prevalence of risk factors for noncommunicable diseases in the Russian population in 2012-2013. results of an essay-rss study. Cardiovascular Therapy and Prevention. 2014;13(6):4-11 (In Russ.) DOI:10.15829/1728-8800-2014-6-4-11.

2. Bandosz P., O’Flaherty M., Drygas W., et al. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ. 2012;344:8136. DOI:10.1136/bmj.d8136.

3. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet. 2003;361:1149-58. DOI:10.1016/S0140-6736(03)12948-0.

4. Roshandel G., Khoshnia M., Poustchi H., et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394:672-83. DOI:10.1016/S0140-6736(19)31791-X.

5. Shlyakhto E.V., ed. Cardiology. National leadership. M.: GEOTAR-Media; 2019 (In Russ.)

6. Asmar R., Topouchian J., Pannier B., et al. Pulse wave velocity as endpoint in large; scale intervention trial. The Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior study. J Hypertens. 2001;19(4):813-8. DOI:10.1097/00004872-200104000-00019.

7. D'elia L., La Fata E., Iannuzzi A., Rubba P.O. Effect of statin therapy on pulse wave velocity: A metaanalysis of randomized controlled trials. Clin Exp Hypertens. 2018;8:1-8. DOI:10.1080/10641963.2017.1411498.

8. Bochenina Y.A., Kuznetsov G.E., Tenchurina L.E. The effect of rosuvastatin on the structural and functional state of endothelium in patients with chronic heart failure of ischemic etiology. Farmateka. 2013;17(250):47-51 (In Russ.)

9. Nissen S., Nicholls S., Sipahy I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA. 2006;295(13):1556-65. DOI:10.1001/jama.295.13.jpc60002.

10. Ridker P., Fonseca F., Genest J., et al. JUPITER Trial Study Group Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol. 2007;100:1659-64. DOI:10.1016/j.amjcard.2007.09.072.

11. Nedogoda S. V., Chumachek E. V., Ledyaeva A. A. et al. Optimization of blood pressure control, organ protection and metabolic disorders using a fixed combination of lisinopril + amlodipine + rosuvastatin in patients with arterial hypertension. Russian Journal of Cardiology. 2018;4(156):49-55 (In Russ.) DOI:10.15829/1560-4071-2018-4-49-55.

12. Blankova Z. N., Aslanyan N. S. The effect of combination therapy on the state of the vascular wall in patients with high cardiovascular risk. Systemic Hypertension. 2017;14(2):51-5 (In Russ.) DOI:10.26442/2075-082X_14.2.51-55.

13. Ageev F.T., Blankova Z.N., Samsonova N.S. The effect of transferring patients with arterial hypertension and high cardio; vascular risk with conventional antihypertensive therapy for therapy with a triple fixed combination with ROZuVAstatin: the ALROSA study. Kardiologiia. 2018;(S3):46-54 (In Russ.)

14. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-357. DOI:10.1097/01.hjh.0000431740.32696.cc.

15. Celermajer D.S., Sorensen K.E., Сooch V.M., et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340:1111-5. DOI:10.2147/VHRM.S17801.

16. Touboul P.J., Hennerici M.G., Meairs S., et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007; 23(1): 75-80. DOI:10.1159/000097034.

17. White W. Blood pressure monitoring in Cardiovascular Medicine and Therapeutics. New Jersey: Humana Press; 2001.

18. Strazzullo P., Kerry S.M., Barbato A., et al. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension. 2007;49(4):792-8. DOI:10.1161/01.HYP.0000259737.43916.42.

19. Mikhin V.P., Zhilyaeva Y.A., Vorotyntseva V.V., et al. Hypolipidemic and pleiotropic efficacy of rosuvastatin in patients with arterial hypertension with high cardiovascular risk under long-term outpatient monitoring. Russian Journal of Cardiology. 2016;(12):90-6 (In Russ.) DOI:10.15829/1560-4071-2016-12-90-96.

20. Schaefer C.A., Blatzheim A.K., Passon S.G., et al. Modulation of carotid strain by statin therapy in atherosclerosis patients. Vasa. 2017;46(2):108-15. DOI:10.1024/0301-1526/a000596.

21. Oesterle A., Laufs U., Liao J.K. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017; Jan 6;120(1):229-243. DOI:10.1161/CIRCRESAHA.116.308537.

22. Maksimov M.L., Ermolaeva A.S., Dralova O.V. Advantages and relevance of the clinical use of the triple combination of an ACE inhibitor perindopril with rosuvastatin and indapamide in patients with arterial hypertension and dyslipidemia. Russian Journal of Cardiology. 2017;(147):139-50 (In Russ.) DOI:10.15829/1560-4071-2017-7-139-150.

23. Karpov Y.A. Triumvirate study: cardio risk reduction; vascular complications in patients with hypertension using a three-component combination of antihypertensive and lipid-lowering drugs. Kardiologiia. 2015;55(9):10-5 (In Russ.)


For citation:


Fedorishina O.V., Protasov K.V., Torunova A.M. Drug Correction of Vascular Remodeling in Patients with Hypertension: Results of 52-Week Prospective Study ARTERIA-AG. Rational Pharmacotherapy in Cardiology. 2020;16(2):213-220. (In Russ.) https://doi.org/10.20996/1819-6446-2020-04-08

Views: 155


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)